Nature Communications (Nov 2024)

Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques

  • Sommer Holmes,
  • Hui Li,
  • Xiaoying Shen,
  • Mitchell Martin,
  • Ryan Tuck,
  • Yue Chen,
  • Elena E. Giorgi,
  • Hélène Fradin Kirshner,
  • Madison Berry,
  • Elizabeth Van Italie,
  • Sravani Venkatayogi,
  • Joshua S. Martin Beem,
  • Robert J. Edwards,
  • Katayoun Mansouri,
  • Ajay Singh,
  • Cindy Kuykendall,
  • Thaddeus Gurley,
  • M. Anthony Moody,
  • Nicole DeNayer,
  • Todd Demarco,
  • Thomas N. Denny,
  • Yunfei Wang,
  • Tyler D. Evangelous,
  • John T. Clinton,
  • Bhavna Hora,
  • Kshitij Wagh,
  • Michael S. Seaman,
  • Kevin O. Saunders,
  • Nicholas Solomotis,
  • Johnathan Misamore,
  • Mark G. Lewis,
  • Kevin Wiehe,
  • David C. Montefiori,
  • George M. Shaw,
  • Wilton B. Williams

DOI
https://doi.org/10.1038/s41467-024-54753-6
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 23

Abstract

Read online

Abstract The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simian-HIV infection. Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 months results in heterologous HIV-1 neutralizing antibodies in 64% of young macaques compared to 18% of adult macaques. Heterologous HIV-1 neutralizing antibodies emerge by 12 months post-infection in young macaques, in association with lower expression of immunosuppressive genes, fewer germinal center CD4 + T regulatory cells, and a lower ratio of CD4 + T follicular regulatory to helper cells. Antibodies from peripheral blood B cells in two young macaques following SHIV infection neutralize 13% of 119 heterologous HIV-1 strains and map to regions of canonical broadly neutralizing antibody epitopes on the envelope surface protein. Here we show that pediatric immunity to SHIV infection in a macaque model may inform vaccine strategies to induce effective HIV-1 neutralizing antibodies in infants and children prior to viral exposure.